Overview

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine directly into the bladder may kill more tumor cells. PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with recurrent bladder cancer that has progressed despite previous Bacillus Calmette-Guerin (BCG).

Phase:

Phase 2

Details

Lead Sponsor:

Southwest Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Gemcitabine